Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscle Development | 5 | 2026 | 72 | 3.500 |
Why?
|
| Muscle, Skeletal | 5 | 2025 | 980 | 2.750 |
Why?
|
| X-Box Binding Protein 1 | 3 | 2026 | 32 | 2.700 |
Why?
|
| Endoribonucleases | 3 | 2026 | 87 | 2.600 |
Why?
|
| MAP Kinase Kinase Kinases | 3 | 2026 | 56 | 2.510 |
Why?
|
| Signal Transduction | 7 | 2026 | 4646 | 2.090 |
Why?
|
| Muscular Atrophy | 4 | 2025 | 84 | 2.050 |
Why?
|
| Cachexia | 2 | 2025 | 57 | 1.800 |
Why?
|
| Myoblasts | 2 | 2024 | 32 | 1.640 |
Why?
|
| Rhabdomyosarcoma | 2 | 2026 | 229 | 1.520 |
Why?
|
| Cell Differentiation | 4 | 2026 | 1907 | 1.360 |
Why?
|
| Magnetic Resonance Imaging | 22 | 2022 | 3742 | 1.220 |
Why?
|
| Brain Neoplasms | 12 | 2022 | 1305 | 1.010 |
Why?
|
| Glioma | 5 | 2015 | 495 | 0.880 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2025 | 127 | 0.880 |
Why?
|
| Cell Fusion | 1 | 2024 | 32 | 0.850 |
Why?
|
| Myositis | 1 | 2025 | 84 | 0.850 |
Why?
|
| TWEAK Receptor | 1 | 2023 | 3 | 0.810 |
Why?
|
| Motor Cortex | 2 | 2015 | 56 | 0.780 |
Why?
|
| Muscular Diseases | 1 | 2024 | 119 | 0.770 |
Why?
|
| Brain Mapping | 5 | 2017 | 379 | 0.760 |
Why?
|
| Cell Communication | 1 | 2023 | 188 | 0.740 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2022 | 58 | 0.720 |
Why?
|
| Respiratory Insufficiency | 1 | 2024 | 246 | 0.690 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2020 | 70 | 0.620 |
Why?
|
| Pancreatic Neoplasms | 1 | 2025 | 735 | 0.600 |
Why?
|
| Mice | 10 | 2026 | 18173 | 0.530 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2018 | 587 | 0.490 |
Why?
|
| Animals | 11 | 2026 | 33676 | 0.450 |
Why?
|
| Glioblastoma | 4 | 2022 | 372 | 0.400 |
Why?
|
| Hand | 1 | 2012 | 93 | 0.340 |
Why?
|
| Muscle Proteins | 2 | 2024 | 401 | 0.340 |
Why?
|
| Brain | 6 | 2018 | 3147 | 0.320 |
Why?
|
| Astrocytoma | 1 | 2010 | 101 | 0.300 |
Why?
|
| Spinal Neoplasms | 2 | 2017 | 76 | 0.290 |
Why?
|
| Cell Proliferation | 2 | 2026 | 2463 | 0.280 |
Why?
|
| Neuroimaging | 1 | 2012 | 381 | 0.280 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2026 | 2007 | 0.280 |
Why?
|
| Cell Line, Tumor | 2 | 2026 | 3713 | 0.280 |
Why?
|
| Image Enhancement | 4 | 2016 | 159 | 0.250 |
Why?
|
| Speech | 2 | 2017 | 63 | 0.240 |
Why?
|
| Unfolded Protein Response | 1 | 2025 | 66 | 0.230 |
Why?
|
| Humans | 32 | 2026 | 130204 | 0.230 |
Why?
|
| Selenoproteins | 1 | 2024 | 13 | 0.210 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2024 | 36 | 0.210 |
Why?
|
| Enzyme Activation | 1 | 2025 | 576 | 0.210 |
Why?
|
| Phosphoproteins | 1 | 2026 | 447 | 0.200 |
Why?
|
| Fibrosis | 1 | 2025 | 420 | 0.200 |
Why?
|
| Cell Movement | 1 | 2026 | 874 | 0.180 |
Why?
|
| Autophagy | 1 | 2025 | 419 | 0.180 |
Why?
|
| Wnt Signaling Pathway | 1 | 2023 | 207 | 0.180 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2026 | 614 | 0.180 |
Why?
|
| Fractures, Spontaneous | 1 | 2002 | 19 | 0.180 |
Why?
|
| Regeneration | 1 | 2024 | 226 | 0.180 |
Why?
|
| Middle Aged | 22 | 2018 | 28315 | 0.170 |
Why?
|
| Spinal Fractures | 1 | 2002 | 48 | 0.170 |
Why?
|
| Muscles | 1 | 2020 | 197 | 0.160 |
Why?
|
| Meningeal Neoplasms | 3 | 2015 | 217 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 977 | 0.150 |
Why?
|
| Oxidative Stress | 1 | 2024 | 790 | 0.150 |
Why?
|
| Contrast Media | 4 | 2016 | 474 | 0.140 |
Why?
|
| Adult | 20 | 2018 | 31035 | 0.140 |
Why?
|
| Phosphorylation | 1 | 2022 | 1570 | 0.140 |
Why?
|
| Male | 21 | 2025 | 64425 | 0.140 |
Why?
|
| Molecular Imaging | 1 | 2018 | 58 | 0.130 |
Why?
|
| Radiation Injuries | 2 | 2011 | 141 | 0.130 |
Why?
|
| Wernicke Area | 1 | 2017 | 1 | 0.130 |
Why?
|
| Cell Adhesion Molecules | 1 | 2018 | 222 | 0.130 |
Why?
|
| Aged | 15 | 2018 | 20818 | 0.130 |
Why?
|
| Neuronavigation | 1 | 2017 | 9 | 0.130 |
Why?
|
| Disease Models, Animal | 2 | 2025 | 4642 | 0.130 |
Why?
|
| Spinal Cord Compression | 1 | 2017 | 30 | 0.120 |
Why?
|
| Hyperthermia, Induced | 1 | 2017 | 50 | 0.120 |
Why?
|
| Membrane Proteins | 1 | 2024 | 1589 | 0.120 |
Why?
|
| Transcription Factors | 1 | 2026 | 2400 | 0.120 |
Why?
|
| Genomics | 3 | 2022 | 1617 | 0.120 |
Why?
|
| Gene Expression Regulation | 1 | 2024 | 2323 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 4694 | 0.120 |
Why?
|
| Cerebral Veins | 1 | 2016 | 23 | 0.120 |
Why?
|
| Skull Base | 1 | 2016 | 49 | 0.120 |
Why?
|
| Language | 1 | 2017 | 219 | 0.110 |
Why?
|
| Anatomic Landmarks | 1 | 2015 | 20 | 0.110 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2016 | 161 | 0.110 |
Why?
|
| Laser Therapy | 1 | 2017 | 242 | 0.110 |
Why?
|
| Female | 20 | 2018 | 70342 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2011 | 2057 | 0.100 |
Why?
|
| Gene Expression | 1 | 2018 | 1482 | 0.100 |
Why?
|
| Spinal Diseases | 2 | 2011 | 46 | 0.100 |
Why?
|
| Preoperative Care | 1 | 2016 | 357 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2015 | 216 | 0.100 |
Why?
|
| Diagnosis, Differential | 3 | 2010 | 1875 | 0.090 |
Why?
|
| Parathyroid Neoplasms | 1 | 2011 | 20 | 0.090 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2012 | 88 | 0.080 |
Why?
|
| Young Adult | 6 | 2018 | 10000 | 0.080 |
Why?
|
| Reference Values | 1 | 2012 | 674 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2018 | 229 | 0.080 |
Why?
|
| Retrospective Studies | 9 | 2022 | 17577 | 0.080 |
Why?
|
| Adenoma | 1 | 2011 | 142 | 0.080 |
Why?
|
| Brain Diseases | 2 | 2003 | 298 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2011 | 157 | 0.080 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 6764 | 0.070 |
Why?
|
| Software | 1 | 2013 | 733 | 0.070 |
Why?
|
| Melanoma | 1 | 2015 | 927 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1320 | 0.070 |
Why?
|
| Hydroxamic Acids | 1 | 2007 | 60 | 0.070 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2007 | 88 | 0.060 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 1799 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 2076 | 0.060 |
Why?
|
| Median Neuropathy | 1 | 2006 | 2 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2007 | 105 | 0.060 |
Why?
|
| Patient Positioning | 2 | 2017 | 48 | 0.060 |
Why?
|
| Lipomatosis | 1 | 2006 | 15 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2010 | 1263 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 2 | 2011 | 635 | 0.060 |
Why?
|
| Fingers | 1 | 2006 | 62 | 0.060 |
Why?
|
| Hamartoma | 1 | 2006 | 51 | 0.060 |
Why?
|
| Muscle Weakness | 1 | 2006 | 88 | 0.060 |
Why?
|
| Bevacizumab | 3 | 2011 | 56 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 324 | 0.050 |
Why?
|
| Spine | 1 | 2004 | 151 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2017 | 820 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2003 | 100 | 0.050 |
Why?
|
| Echo-Planar Imaging | 1 | 2002 | 21 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2022 | 1578 | 0.050 |
Why?
|
| Choroid Plexus | 1 | 2002 | 25 | 0.050 |
Why?
|
| Diffusion | 1 | 2002 | 56 | 0.040 |
Why?
|
| Cerebral Ventricles | 1 | 2002 | 80 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 747 | 0.040 |
Why?
|
| Cysts | 1 | 2002 | 81 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 1001 | 0.040 |
Why?
|
| Mutation | 1 | 2015 | 6062 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2022 | 285 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2011 | 565 | 0.040 |
Why?
|
| Hematologic Neoplasms | 1 | 2003 | 314 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 1797 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2003 | 655 | 0.040 |
Why?
|
| Necrosis | 2 | 2011 | 193 | 0.040 |
Why?
|
| Adolescent | 4 | 2018 | 20816 | 0.030 |
Why?
|
| Prognosis | 2 | 2018 | 4847 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 89 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2018 | 331 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 2003 | 572 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2017 | 176 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2017 | 99 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 968 | 0.030 |
Why?
|
| Anesthesia, General | 1 | 2017 | 140 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 152 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 303 | 0.030 |
Why?
|
| Veins | 1 | 2016 | 95 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2003 | 1272 | 0.030 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 45 | 0.020 |
Why?
|
| Triiodobenzoic Acids | 1 | 2011 | 29 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 53 | 0.020 |
Why?
|
| Thoracic Vertebrae | 1 | 2011 | 74 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2011 | 108 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 223 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 422 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 239 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 610 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2010 | 11 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2010 | 86 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2015 | 12824 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 609 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2011 | 269 | 0.020 |
Why?
|
| Meningioma | 1 | 2011 | 148 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2891 | 0.020 |
Why?
|
| Capsules | 1 | 2007 | 21 | 0.020 |
Why?
|
| Anorexia | 1 | 2007 | 23 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1613 | 0.020 |
Why?
|
| Time Factors | 2 | 2007 | 6166 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 6407 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 220 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 902 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 5166 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2007 | 706 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 712 | 0.010 |
Why?
|
| Spinal Cord Diseases | 1 | 2004 | 32 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1604 | 0.010 |
Why?
|
| Biopsy | 1 | 2007 | 1240 | 0.010 |
Why?
|
| Models, Structural | 1 | 2002 | 34 | 0.010 |
Why?
|
| Fourier Analysis | 1 | 2002 | 54 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 2002 | 141 | 0.010 |
Why?
|
| Syndrome | 1 | 2003 | 1156 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2002 | 498 | 0.010 |
Why?
|
| Hydrocephalus | 1 | 2002 | 242 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 3030 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2002 | 2591 | 0.000 |
Why?
|